NCT01579383View on ClinicalTrials.gov

Safety Tolerability and Pharmacokinetics of ALD403

PHASE1CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

December 31, 2012

Study Completion Date

April 30, 2013

Conditions
Migraine Disorders
Interventions
BIOLOGICAL

ALD403

Single Dose IV infusion on Day 1

BIOLOGICAL

ALD403

Single Dose subcutaneous injection on Day 1

BIOLOGICAL

Sumatriptan

Single Dose subcutaneous injection on Day 1

Trial Locations (1)

3004

Centre for Clinical Studies, Nucleus Network, Melbourne

Sponsors
All Listed Sponsors
lead

Alder Biopharmaceuticals, Inc.

INDUSTRY

NCT01579383 - Safety Tolerability and Pharmacokinetics of ALD403 | Biotech Hunter | Biotech Hunter